Tagged with B

Pharma In an exclusive interview at the eyeforpharma Barcelona Summit 2016, Janssen EMEA’s Jane Griffiths speaks out about patient-centricity, sustainability and the dawning of a new world of healthcare. What’s been keeping you most busy in recent months? We have, for the third consecutive year, topped IDEA Pharma’s Productive Innovation Index (PII), which…

Pharma Having successfully accomplished a four-year turnaround exercise and with a fresh capital injection from a leading Italian PE firm, SIFI executive chairman Fabrizio Chines has ambitious growth objectives for the coming years, and is investing in R&D projects including the development of an ophthalmic orphan drug. The Italian pharmaceutical industry…

Pharma The AIFP’s Jakub Dvořáček explains the recently launched tool for information disclosure between pharmaceutical companies and doctors, highlighting the significance it holds for industry and country. Furthermore, he reviews the Czech Republic’s attractiveness as a location for pharma companies. When we met you in 2012, you named re-exporting and a…

Pharma Outspoken Italian Managing Director of Israeli-based Teva, Hubert Puech d’Alissac, talks about his passion for social responsibility, adapting to the new realities of patient care in the digital age, and his aspirations for the “Made in Italy” brand. When we covered Italy in 2009 your predecessor Mr. Walter Medda spoke…

Pharma Marc Alexander Burmeister of B. Braun France speaks about the country’s role as a production hub for B. Braun’s global operations, its 2020 strategy to reach USD 200 million in investments, and the French affiliate’s growth through acquisition of SMEs. The B. Braun Group recently shared its Strategy 2020 in…

Pharma Giorgio Bruno, CEO of Recipharm Italy, gives an insight into the success factors of the CDMO, discusses the recent acquisition of Mitim, and explains how this acquisition helps Recipharm not only achieve their growth ambitions but also provide better services to its clients. You were appointed CEO of Recipharm Italy…

Italy The president of Chiesi explains how innovation and a strong focus on quality have led to outstanding growth and have established the Italian family-run business as a significant pharma player around the world. He furthermore elaborates on Chiesi’s strategy to maintain growth abroad and reviews the challenge of attracting and…

Pharma Jean-Paul Berthomé, the CEO of Laboratoires Expanscience, talks about the company’s global ambitions, flagship products and strategies to tackle challenges in emerging economies. With a presence in highly saturated markets, proper positioning has been at the heart of their branding success. Laboratoires Expanscience has over 60 years’ history, with well-known…

Pharma Family-owned Laboratori Baldacci is something of a rare breed in an industry dominated by multinational players. The senior research manager discusses the history of the company as well as how it plans to leverage its portfolio of innovative products and internationalization to drive growth in future. Could you please provide…

Pharma As CEO of the newly formed government agency Business France, Muriel Pénicaud is passionate about championing French innovation and creativity, particularly in life sciences. She tells us about her organization’s key objectives, ongoing efforts to change perceptions about France’s business environment, and her ‘bilingualism’ in the worlds of business and…

Pharma The dynamic Director of ESCP Europe’s Master in Biopharmaceutical Management talks about being the reference higher education institution for programs catering to the biopharma sector, plans for more international visibility, and some notable alumni of the university’s executive level curriculum. ESCP Europe appears to have a special connection to the…

Pharma Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the company and the growth ambitions for the affiliate over the next few years. You have extensive experience in the generics…